Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
Project leader/senior scientist at UniBern.
2 years in pharma industry.
8 years of research activity on the ECS
Full Professor at UniBern.
Collaboration with pharma industry.
10+ years of research activity on the ECS.
Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510.
Synendos transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders.
Synendos has been selected as a finalist of the Swiss Economic Award 2025 in the category Deeptech / Life Sciences. LinkedIn post
Synendos has been selected for the Bio-Neuroscience Award for the "Best Pitch" after our CEO Andrea Chicca's presentation on our clinical...
Synendos is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch, “CNS Drug Discovery in...